The Interministerial Commission on Prices (CIPM) has unanimously approved drugs against breast cancer get stronger (trastuzumab deruxtecán, from Daiichi Sankyo) and Trodelvy (sacituzumab govitecan-hziy, from Gilead). This was decided on 26 September, after both drugs did not appear on the list published following the last meeting.
Both patient associations and many regional administrations have been calling for the approval of these drugs for some time. This is the case of the Community of Madrid, which recalls that, Since December 2023, the approval of drug financing has been brought to the CIPM “up to four times” for the care of patients with metastatic breast cancer.”
And this region has always had the same criterion: a favorable vote. For this reason, the Madrid Health Minister, Fatima Matutehas welcomed the news, pointing out that “the measures have finally been approved drugs that save and prolong lives of patients with breast cancer, as the Community of Madrid has supported and insisted on from the very first minute.”
“There are approximately 210 patients in our community, but even if it were just one life, it is priceless,” Matute said. In this regard, he pointed out that They will continue to insist to the Ministry of Health to reduce the time during which an oncological drug is available to the population.. “We are at the back of the queue; 700 days, which is unacceptable, compared to 180 in Europe,” the Madrid councillor stressed. For this reason, the Community of Madrid will “continue to insist that our entire population receive the best and as soon as possible.”
